Medtronic PLC announced Wednesday plans to separate its diabetes business into a new public company, just as the medical-device company reported quarterly results showing that the business was its ...

Medtronic's stock has been an underwhelming investment to hold on to in recent years. While it's up around 4% this year, over a five-year period its returns are negative -- down 15%.

Medtronic ’s decision to spin out its diabetes division into a separate entity marks a major shift — one that allows the medical device giant to shed a lower-margin, consumer-facing business ...

Medtronic reported a fourth quarter global revenue of nearly $9 billion on Wednesday, totaling more than $33.5 billion globally for fiscal year 2025.

Medical-device maker Medtronic MDT -0.13% plans to separate its diabetes business into a stand-alone company, the company said, in a move that hives off a division that had struggled but recently ...

Medtronic is among the world’s largest makers of medical devices. - Jenn Ackerman for WSJ Medical-device maker Medtronic plans to separate its diabetes business into a stand-alone company, the ...

By getting rid of the diabetes segment, Medtronic (NYSE: MDT) aims to focus on its more profitable segments—making devices for cardiovascular, neuroscience, and medical surgery.

Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company and forecast 2026 ...

Over the last five years, Medtronic's stock has shown a favorable one-day return following its earnings announcements in 53% of instances. These favorable returns have had a median of 2.5% and a ...

Medtronic shares slumped Tuesday after the medical device maker missed sales forecasts. The revenue miss came as sales of its stapling and blood oxygen management products slowed. Despite Tuesday ...

Medtronic MDT said third-quarter revenue fell 0.4% in its medical-surgical unit, one of the medical-products company’s four main business lines, along with neuroscience, cardiovascular and diabetes.